Name | IWR-1-endo |
---|---|
Synonyms |
4-[(1R,2S,6R,7S)-3,5-Dioxo-4-azatricyclo[5.2.1.0]dec-8-en-4-yl]-N-(8-quinolinyl)benzamide
4-[(1R,2S,6R,7S)-3,5-Dioxo-4-azatricyclo[5.2.1.0]dec-8-en-4-yl]-N-(quinolin-8-yl)benzamide Benzamide, 4-[(3aR,4S,7R,7aS)-1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl]-N-8-quinolinyl- IWR-1 |
Description | IWR-1 is a tankyrase inhibitor which inhibits Wnt/β-catenin signaling pathway. |
---|---|
Related Catalog | |
Target |
IC50: 180 nM (Wnt) |
In Vitro | Both IWR-1 and XAV939 act as reversible Wnt pathway inhibitors and exhibit similar pharmacological effects in vitro. IWR-1 exerts its effect via interaction with Axin, while XAV939 binds TNKS directly[1]. IWR-1 (10 μM) induces stabilization of β-catenin disruption complex. IWR-1 (10 μM) is added to the medium together with MIF, the size of cell colonies is extremely decreased, and that indicates the promoting effect of MIF on NSPC proliferation is inhibited by IWR-1 in any MIF concentration group. 2, 5 and 10 μM of IWR-1 significantly inhibits the proliferation of NSPC dose-dependently. IWR-1 inhibites the promoting effect of MIF on NSPC differentiation to neuron lineage[2]. IWR-1 treatment in the presence of maximal stimulatory dose of FSH (0.5 ng/mL) results in a dose dependent inhibition of the stimulatory effect of FSH with > 75% inhibition observed at the maximal inhibitory dose of IWR-1 (1 µM). IWR-1 treatment partially reverses the FSH-induced inhibition of granulosa cell CARTPT mRNA expression[3]. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 643.9±55.0 °C at 760 mmHg |
Molecular Formula | C25H19N3O3 |
Molecular Weight | 409.437 |
Flash Point | 343.2±31.5 °C |
Exact Mass | 409.142639 |
PSA | 79.37000 |
LogP | 2.65 |
Appearance | white to beige |
Vapour Pressure | 0.0±1.9 mmHg at 25°C |
Index of Refraction | 1.741 |
Storage condition | Store at RT |
Water Solubility | DMSO: soluble5mg/mL, clear |